To discuss a potential Pradaxa bleeding lawsuit with one of the experienced and compassionate defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit website, www.FightForVictims.com.
Melville, NY (PRWEB) September 11, 2012
Andres Alonso and David Krangle, founding partners of Alonso Krangle LLP, a law firm dedicated to fighting for the rights of serious defective drug injury victims, reports that the maker of Pradaxa, Boehringer Ingelheim Pharmaceuticals, has failed in its bid to have a Pradaxa bleeding lawsuit dismissed. The Pradaxa lawsuit, which is pending in U.S. District Court, Southern District of Illinois, was filed on behalf of a woman who suffered a subdural hematoma and severe gastrointestinal bleeding, allegedly due to her use of Pradaxa. (Case 3:12-cv-00611-DRH-SCW)
As stated in court documents, the complaint is one of many Pradaxa bleeding lawsuits pending before U.S. Chief Judge David R. Herndon in the Southern District of Illinois alleging Boehringer Ingelheim failed to adequately warn doctors and patients that Pradaxa can sometimes cause severe, and potentially life-threatening, internal bleeding. In August, Judge Herndon was tapped by the U.S. Judicial Panel on Multidistrict Litigation to oversee the Pradaxa (Dabigatran Etexilate) Products Liability Litigation (MDL No. 2385). There is still time for victims of Pradaxa bleeding side effects to file claims in this litigation. Alonso Krangle LLP offers free Pradaxa bleeding side effects lawsuit evaluations to bleeding injury victims, including any Pradaxa user who has suffered:
- Cerebral Hemorrhage, or Brain Bleeds
- Gastrointestinal Bleeding, or Stomach Bleeds
- Kidney Bleeding
- Heart Attack
- Death from Serious Internal Bleeding
To discuss a potential Pradaxa bleeding lawsuit with one of the experienced and compassionate defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
As stated in court documents, Pradaxa, which was introduced by Boehringer Ingelheim in October 2010, was supposed to replace Coumadin (warfarin) for prevention of stroke among patients with non-valvular atrial fibrillation. In December 2011, the U.S. Food & Drug Administration (FDA) released a safety communication warning patients of a possible increased risk for bleeding events while taking Pradaxa. More recently, a report issued by the Institute for Safe Medication Practices reported that Pradaxa accounted for over 3000 serious adverse events in 2011, including over 500 patient deaths.
In its motion to dismiss Carole Richardson’s Pradaxa bleeding lawsuit, Boehringer Ingelheim argued, among other things, that her failure to warn claims should be dismissed since Pradaxa’s label does include a warning about serious, possibly fatal bleeding that is sometimes associated with the use of the drug. The company further argued that Richardson’s failure to warn claims were barred by comment k to the Restatement (Second) of Torts § 402 which holds that “there are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use. These are especially common in the field of drugs”
As stated in court documents, in his Order dated July 24, 2012, Judge Herndon rejected those arguments, pointing out that Richardson’s allegations go beyond a mere failure to warn that Pradaxa is associated with the risk of serious and sometimes fatal bleeding. Rather, Richardson’s complaint specifically addresses the fact that if serious Pradaxa bleeding does occur, there is no effective way to reverse the side effect. He also rejected the company’s comment k argument, writing that it is unclear whether comment k will apply to Pradaxa, as it does not cover all drugs, and must be decided on a case-by-case basis.
As stated in court documents, Judge Herndon also allowed Richardson’s fraud allegations to go forward, noting that her claim “alleges the Pradaxa Marketing Campaign, as well as Pradaxa’s labeling and prescribing information, contained knowing misrepresentations or omissions regarding the safety and efficacy of Pradaxa,” including its safety in relation to warfarin, and the drug’s lack of an effective reversal agent.
Alonso Krangle LLP continues to offer free legal evaluations to the victims of Pradaxa side effects. To discuss a potential claim with one of the experienced Pradaxa bleeding side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website http://www.FightForVictims.com.
About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
Alonso Krangle LLP
445 Broad Hollow Road
Melville, New York 11747